While numbers indicate that the risks of COVID-19 still outweigh potential vaccine side effects, the current pause in vaccine distribution demonstrate the system is working and the public is onboard.
Pseudoviruses help determine the success of COVID-19 vaccines and antibody therapies
Assays using pseudoviruses have been indispensable in our efforts to halt the current pandemic.
Delaying second dose of COVID-19 vaccine has benefits in the short term, but depends on immunity
The strength of immune responses after the first dose of COVID-19 vaccines could make or break this strategy and policy makers need to be able to adapt.
What COVID-19 vaccine should I get? Whichever one you are offered, say experts
First and foremost, the goal is to keep people out of hospitals. The good news is all of the currently approved vaccines do just that.
Russian COVID-19 vaccine shows 91.6% efficacy in phase 3 trial
Russia’s Sputnik V coronavirus vaccine gives around 92% protection against COVID-19, results published in The Lancet reveal.
New method to assist fast-tracking of vaccines for pre-clinical tests
Nvel tuberculosis vaccine demonstrated strong immune response in mice.
The first COVID-19 vaccines are here, but challenges remain
Whilst vaccines against COVID-19 show there is light at the end of the tunnel, three main challenges still need to be addressed.
Oxford–AstraZeneca COVID-19 vaccine shown to be safe and effective
The results of the company’s COVID-19 vaccine clinical trials are the first to be published in a peer-reviewed journal.
Pfizer/BioNTech vaccine approved in the UK for immediate emergency use
The companies announce the first emergency approval of their mRNA vaccine against COVID-19, with rollout to begin next week.
Moderna’s COVID-19 vaccine shows 95% efficacy
US company second to report impressive efficacy for its COVID-19 vaccine candidate.